A5046570651- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- RNA Research and Splicing
- RNA modifications and cancer
- Salivary Gland Tumors Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Retinal Imaging and Analysis
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Cancer and Skin Lesions
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Geophysics and Sensor Technology
- Gastric Cancer Management and Outcomes
- RNA Interference and Gene Delivery
- Retinal Diseases and Treatments
- Gastrointestinal Tumor Research and Treatment
- Ear and Head Tumors
- Acute Lymphoblastic Leukemia research
- Hematological disorders and diagnostics
- Seismic Waves and Analysis
- Silk-based biomaterials and applications
- Single-cell and spatial transcriptomics
National Taiwan University Hospital
2014-2025
National Taiwan University
2016-2024
Shanghai Cell Therapy Research Institute
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2018-2021
Wellcome Sanger Institute
2016
Zero to Three
2014
Taipei Institute of Pathology
2013
The Ohio State University
2010
National Chung Cheng University
2002
Heterozygous somatic mutations affecting the spliceosome gene SF3B1 drive age-related clonal hematopoiesis, myelodysplastic syndromes (MDS) and other neoplasms. To study their role in such disorders, we generated knock-in mice with hematopoietic-specific expression of Sf3b1-K700E, commonest type mutation MDS. Sf3b1K700E/+ animals had impaired erythropoiesis progressive anemia without ringed sideroblasts, as well reduced hematopoietic stem cell numbers host-repopulating fitness. understand...
Abstract In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and 2022 World Health Organization (WHO-2022) classification. These contemporary exhibit numerous shared features but also diverge significantly in terminology definition of new entities. Thus, we retrospectively validated ICC WHO-2022 found that both promoted efficient segregation this heterogeneous disease. After examining...
Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for optimization. Recently, molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters, cytogenetic abnormalities, mutation topography was proposed. This study validated the IPSS-M in 649 patients with primary MDS (based on 2022 Consensus Classification [ICC]) compared its power to those of IPSS revised (IPSS-R). Overall, 42.5%...
Aberrant alternative splicing (AS) is a hallmark of cancer development. However, there are limited data regarding its clinical implications in myelodysplastic syndrome (MDS). In this study, we performed an in-depth analysis global AS 176 primary MDS patients with 20 normal marrow transplant donors as reference. We found that 26.9% the expressed genes genome-wide were aberrantly spliced compared donors. These aberrant related to pathways involved cell proliferation, adhesion and protein...
Summary Dedicator of cytokinesis 1 ( DOCK1 ), a guanine nucleotide exchange factor for the small GTPase Rac, has been implicated in various biological processes, but its pathological roles acute myeloid leukaemia (AML) remain unexplored. In this study, we analysed clinical impacts expression 341 patients with de novo non‐M3 AML treated standard chemotherapy. The results showed that high is an independent adverse prognostic factor. Consistent this, experiments using cell lines, xenografts and...
The revised International Prognostic Scoring System (IPSS‐R) was recently developed to better assess the clinical outcome of adult patients with myelodysplastic syndrome (MDS). In this study, we aimed investigate prognostic impact new risk model on 555 MDS in Taiwan. Generally, IPSS‐R could discriminate regarding leukemia evolution and overall survival our cohort it further refined stratification all IPSS categories. However, not find inter‐group difference between very low subgroups both...
Abstract Aberrant alternative splicing (AS) is involved in leukemogenesis. This study explored the clinical impact of alterations global AS patterns 341 patients with acute myeloid leukemia (AML) newly diagnosed at National Taiwan University Hospital and validated it using The Cancer Genome Atlas (TCGA) cohort. While studying normal cord blood CD34 + /CD38 − cells, we found that AML cells exhibited significantly different patterns. mutated TP53 had a particularly high degree genome‐wide...
Abstract In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and 2022 World Health Organization (WHO-2022) classification. These contemporary exhibit numerous shared features but also diverge significantly in terminology definition of new entities. Thus, we retrospectively validated ICC WHO-2022 found that both promoted efficient segregation this heterogeneous disease. After examining...
Aberrant alternative splicing (AS) contributes to leukemogenesis, but reports on the clinical and biological implications of aberrant AS in acute myeloid leukaemia (AML) remain limited. Here, we used RNA-seq analyse AML cells from 341 patients, comparing them healthy CD34
Objective: To investigate the clinical features and prognosis of extranodal nasal-type NK/T-cell lymphoma extra-upper aerodigestive tract (extra-UADT NKTCL). Methods: The data 159 patients with extra-UADT NKTCL from China Lymphoma Collaborative Group (CLCG) database between November 2001 December 2015 were retrospectively analyzed. Kaplan-Meier survival analysis Log-rank test used to evaluate prognosis. Cox regression model is for multi-factor analysis. Results: Extra-UADT commonly occurs in...
Salivary gland adenocarcinoma is a rare type of head and neck cancer often has aggressive behavior with propensity to recur metastasize. Currently, there are no standard treatment guidelines. Surgery however, the mainstay in resectable disease radiation also considered for most patients after surgery. Systemic chemotherapy reserved metastatic cases, but its results disappointing. Recent development molecular biology shown that salivary caner several changes which may guide potential...
Abstract Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for optimization. Recently, molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters, cytogenetic abnormalities, mutation topography was proposed. This study validated the IPSS-M in 649 patients with primary MDS (based on 2022 Consensus Classification [ICC]) compared its power to those of IPSS revised (IPSS-R). Overall,...